Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Purchases 66,057 Shares

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall purchased 66,057 shares of Immunome stock in a transaction on Thursday, November 21st. The shares were acquired at an average cost of $9.54 per share, for a total transaction of $630,183.78. Following the completion of the transaction, the chief executive officer now owns 485,693 shares of the company’s stock, valued at $4,633,511.22. This represents a 15.74 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Immunome Price Performance

Shares of IMNM stock opened at $11.15 on Tuesday. The company’s fifty day moving average price is $12.49 and its two-hundred day moving average price is $13.55. The firm has a market capitalization of $695.98 million, a P/E ratio of -1.37 and a beta of 1.82. Immunome, Inc. has a 12 month low of $6.93 and a 12 month high of $30.96.

Analysts Set New Price Targets

A number of analysts recently weighed in on IMNM shares. Stephens assumed coverage on shares of Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price target for the company. Piper Sandler decreased their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Friday, October 25th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $28.83.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Arizona State Retirement System grew its stake in Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares in the last quarter. Clear Creek Financial Management LLC boosted its stake in shares of Immunome by 18.2% during the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock valued at $317,000 after buying an additional 4,035 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after buying an additional 4,129 shares in the last quarter. Cerity Partners LLC increased its stake in shares of Immunome by 10.5% in the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after buying an additional 5,043 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in Immunome in the second quarter valued at $81,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.